Skip to main content
. 2018 Jul 20;21(7):513–518. [Article in Chinese] doi: 10.3779/j.issn.1009-3419.2018.07.02

1.

患者的临床特征

Clinical characteristics of patients

Category n (%)
  EGFR: epidermal growth factor receptor; ALK: anaplasticlymphoma kinase.
Age (yr)
  ≥60 18 (29.0)
   < 60 44 (71.0)
Gender
  Male 21 (33.9)
  Female 41 (66.1)
Smoking status
  Ever 56 (90.3)
  Never 6 (9.7)
EGFR mutation
  Positive 30 (48.4)
  Negative 32 (51.6)
ALK rearrangement
  Positive 13 (21.0)
  Negative 49 (79.0)
Driver mutation
  Yes 43 (69.4)
  No 19 (30.6)
Brain metastases
  Yes 28 (45.2)
  No 34 (54.8)
Bone metastases
  Yes 25 (40.3)
  No 37 (59.7)
Cycles of bevacizumab
  ≤6 32 (51.6)
   > 6 30 (48.4)
Platinum-based regimens
  Yes 24 (38.7)
  No 38 (61.3)